Charcot (neuropathic) arthropathy of elbow due to Syringomyelia - review of 50 pts. Median age 45 yrs, 2/3 isolated elbow arthritis; other joints: shoulder > wrist > MCPs/IPs. 2/3 had Chiari malformations, sensory/motor deficits, or ulnar neuropathy https://t.co/KjOpAKxs6i https://t.co/87Asmlzq3K

Matched cohort study of survival in 1139 incident systemic sclerosis pts & 5613 controls. W/ median F/U of 5-6 yrs, deaths were 268 vs 554. 5 Yr survival was lower 79.8% vs 92.9% (10yr survival 67.7% vs 84.8%). SSc had higher 1 yrs mortality (HR 3.7) https://t.co/rGlTWUVVMU https://t.co/XeKnjldgye

Review of VTE risk with JAK inhibitors - Tofacitinib: 10mg or 5 mg bid - PE rates 0.5 & 0.3/100PY; higher w/ risk factors, VTE 0.35/100PY - Baricitinib: IR of DVT/PE was 0.5/100PY - Filgotinib: 200mg VTEs 0.2/100PY Most VTE occured in LT extension of RCT https://t.co/xeX4wj4cWU https://t.co/CJV2h9zO9a

Axial Psoriatic Arthritis and Ankylosing Spondylitis with Psoriasis A cohort analysis from Toronto suggests that axial psoriatic arthritis (PsA) is distinctly different from axial ankylosing spondylitis (AS) with psoriasis. https://t.co/9rFGMLtV5Z https://t.co/3L4mid8i0n

Anti-rheumatics drug market accounted for $57 billion in sales in 2018 and is expected to reach nearly $72 billion by 2026, registering a CAGR of 2.9% from 2019 to 2026. https://t.co/X77cx5QM4G https://t.co/eNCvemksWK

Look-alike Humans identified by facial recognition algorithms identify found to share common genetic sequences such as face trait variants. DNA methylation & microbiome profiles only contribute modestly to human likeness. https://t.co/2KjFAmhPvi https://t.co/RBjHObv2RU

73 #RA pregnancies w/ live births. 88% were in remission/low disease before conception. RA flares occurred in 37% (in 1st &2nd trim). Preterm assoc w/ Flares; flares more likely if bDMARD D/C @ +Preg test (55% w/ flare vs. 30% w/o flare, p 0.03, OR 2.9) https://t.co/hVtUuX3lfr https://t.co/bFbyQZbcim

Chinese study of 215 Bx proven #SLE pts - all rx w/ IV CTX+steroids. Responders were given either AZA or leflunomide. Renal outcomes were same w/ LEF or AZA as maintenance. Flares (16% vs 18%), Time to flare (16 v 14 mos), AE, proteinuria https://t.co/Ad7Ec4OPco https://t.co/NoKAgiMKrK

Survey of 3357 retired Olympians (45 yrs) shows same OA rates as 1735 gen population (41yrs) - #OA in 23% (knee 7.4%, hip, ankle). OA from Injury, age, obesity. Prior knee/hip injury increased OA rates significantly (aOR 1.51/4.03) https://t.co/JwaAidkGG1 https://t.co/30Zm7bDWUG

Cochrane review of Stem cell transplantation in systemic sclerosis (3RCTs w/ 125 pts). Non‐myeloablative & myeloablative selective HSCT had moderate evidence for improved survival, skin thickness & function. But these had high Serious AE rates. https://t.co/sGzWYLwcAZ https://t.co/7JiR0fe3GY

JAK-pot study of 19 registries, 31,846 RA pts Rx w/ new drugs shows equal CDAI efficacy for TNFi (54%), ABA (50%), IL-6i (55%), & JAKi (56%). Most D/C for LOE. Compared to TNFi, JAKi and IL-6i were d/c more for adverse events, less for ineffectiveness https://t.co/FlqPUVdWaC https://t.co/BZnpwtB8SY

Study of 209 Early RA (<1yr) pts found 23 (11%) with Drug Free Remission (DFR) after 74 mos of F/U; DFR maintained x 48 mo (18–82). DFR was assoc w/ early persistence on Therapy (HR 3.84). Adhering to prescribed treatment may lead to DFR https://t.co/WAX6RWhToU https://t.co/ChlbHDDKCZ